ATE478656T1 - Biologisch abbaubare polymerzusammensetzungen, zusammensetzungen und damit in beziehung stehende verwendungen - Google Patents

Biologisch abbaubare polymerzusammensetzungen, zusammensetzungen und damit in beziehung stehende verwendungen

Info

Publication number
ATE478656T1
ATE478656T1 AT02756268T AT02756268T ATE478656T1 AT E478656 T1 ATE478656 T1 AT E478656T1 AT 02756268 T AT02756268 T AT 02756268T AT 02756268 T AT02756268 T AT 02756268T AT E478656 T1 ATE478656 T1 AT E478656T1
Authority
AT
Austria
Prior art keywords
compositions
biodegradable polymer
polymers
related uses
polymer compositions
Prior art date
Application number
AT02756268T
Other languages
English (en)
Inventor
Justin Hanes
Jie Fu
Jennifer Fiegel
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Application granted granted Critical
Publication of ATE478656T1 publication Critical patent/ATE478656T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Polyethers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Dental Preparations (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
AT02756268T 2001-06-22 2002-06-21 Biologisch abbaubare polymerzusammensetzungen, zusammensetzungen und damit in beziehung stehende verwendungen ATE478656T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29972901P 2001-06-22 2001-06-22
PCT/US2002/019772 WO2003000237A2 (en) 2001-06-22 2002-06-21 Biodegradable polymer coompositions

Publications (1)

Publication Number Publication Date
ATE478656T1 true ATE478656T1 (de) 2010-09-15

Family

ID=23156038

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02756268T ATE478656T1 (de) 2001-06-22 2002-06-21 Biologisch abbaubare polymerzusammensetzungen, zusammensetzungen und damit in beziehung stehende verwendungen

Country Status (7)

Country Link
US (1) US7163697B2 (de)
EP (1) EP1406593B1 (de)
JP (1) JP4758607B2 (de)
AT (1) ATE478656T1 (de)
AU (1) AU2002322289A1 (de)
DE (1) DE60237449D1 (de)
WO (1) WO2003000237A2 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE424722T1 (de) * 2001-11-23 2009-03-15 Univ Rutgers Verbesserte synthese von polyanhydriden
US7351749B2 (en) * 2002-12-16 2008-04-01 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Process for manufacture of personal care products utilizing a concentrate water phase
US7662864B2 (en) * 2003-06-04 2010-02-16 Rutgers, The State University Of New Jersey Solution polymerization processes to prepare a polymer that degrades to release a physiologically active agent
WO2005044236A1 (en) * 2003-10-27 2005-05-19 Control Delivery Systems, Inc. Suspension delivery system for the sustained and controlled local release of pharmaceuticals
JP2005206491A (ja) * 2004-01-21 2005-08-04 Medgel Corp 肺気腫を治療するための経肺投与用製剤
US8957034B2 (en) * 2004-01-28 2015-02-17 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
ES2407979T3 (es) * 2004-12-10 2013-06-17 Kala Pharmaceuticals, Inc. Copolímeros de bloques de poli(éter-anhídrido) funcionalizados
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
FR2887886B1 (fr) † 2005-07-01 2010-01-08 Oreal Polymere cationique neutralise, composition le comprenant et procede de traitement cosmetique
US20070225472A1 (en) * 2006-03-23 2007-09-27 Varshney Sunil K Polyanhydride polymers and their uses in biomedical devices
WO2007123793A2 (en) * 2006-04-04 2007-11-01 Stc.Unm Swellable particles for drug delivery
US20080014170A1 (en) * 2006-07-14 2008-01-17 Olexander Hnojewyj Drug delivery polyanhydride composition and method
ITMI20061539A1 (it) * 2006-08-02 2008-02-03 Mediolanum Pharmaceuticals Ltd Impianti sottocutanei in grado di rilasciare il principio attivo per un periodo prolungato di tempo
WO2008021133A2 (en) 2006-08-09 2008-02-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
JP2010502713A (ja) * 2006-09-08 2010-01-28 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘液を通る輸送を増強するための組成物および方法
US20090169628A1 (en) 2006-10-17 2009-07-02 Armark Authentication Technologies, Llc Article and method for focused delivery of therapeutic and/or diagnostic materials
NO20065147L (no) * 2006-11-08 2008-05-09 Ntnu Tech Transfer As Nanokompositter basert på cellulosewhiskers og celluloseplast
WO2008109483A1 (en) 2007-03-02 2008-09-12 The Board Of Trustees Of The University Of Illinois Particulate drug delivery
US8623397B2 (en) * 2007-04-13 2014-01-07 The Regents Of The University Of Michigan Delivery device and method for forming the same
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
US20080311172A1 (en) * 2007-04-25 2008-12-18 Schapira Jay N Programmed-release, nanostructured biological construct
EP2242481A1 (de) * 2007-12-31 2010-10-27 Armark Authentication Technologies, LLC Artikel und verfahren zum gezielten ausbringen von therapeutischen und/oder diagnostischen materialien
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
JP5713897B2 (ja) * 2008-07-16 2015-05-07 エボニック コーポレイションＥｖｏｎｉｋ Ｃｏｒｐｏｒａｔｉｏｎ 生理活性ペプチドを含有する微粒子を調製するためのプロセス
PL2341905T5 (pl) * 2008-09-04 2024-01-15 Amylin Pharmaceuticals, Llc Preparaty o przedłużonym uwalnianiu z wykorzystaniem niewodnych nośników
US8822610B2 (en) 2008-12-22 2014-09-02 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US8815971B2 (en) 2008-12-22 2014-08-26 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US8173750B2 (en) 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
US8569421B2 (en) 2009-04-23 2013-10-29 ATRP Solutions, Inc. Star macromolecules for personal and home care
US9783628B2 (en) 2009-04-23 2017-10-10 ATRP Solutions, Inc. Dual-mechanism thickening agents for hydraulic fracturing fluids
WO2014036498A2 (en) 2012-08-30 2014-03-06 ATRP Solutions, Inc. Dual mechanism thickening agents for hydraulic fracturing fluids
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
WO2011084458A2 (en) * 2009-12-15 2011-07-14 The Johns Hopkins University Polymer-based compositions and methods for treatment of peritoneal disorders
US9587064B2 (en) 2010-12-08 2017-03-07 ATRP Solutions, Inc. Salt-tolerant star macromolecules
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP3808339B1 (de) 2012-05-03 2025-11-12 Alcon Inc. Pharmazeutische nanopartikel mit verbessertem mukosalem transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
JP6360039B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
CA2899349C (en) 2013-02-04 2021-09-21 ATRP Solutions, Inc. Salt-tolerant star macromolecules
HK1217092A1 (zh) 2013-02-15 2016-12-23 Kala Pharmaceuticals, Inc. 治疗性化合物及其用途
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
AU2014219024B2 (en) 2013-02-20 2018-04-05 KALA BIO, Inc. Therapeutic compounds and uses thereof
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US20170119683A1 (en) * 2014-04-28 2017-05-04 The Johns Hopkins University Biopolymer-encapsulated glycosyl transferase inhibitor compositions and methods for treating diabetes and cardiac indications
US10023521B2 (en) 2014-06-13 2018-07-17 Rutgers, The State University Of New Jersey Process and intermediates for preparing poly(anhydride-esters)
EP3164429A4 (de) 2014-07-03 2017-12-20 ATRP Solutions, Inc. Tensidkompatible stern-makromoleküle
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CA2987766A1 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
SG11201803663XA (en) 2015-11-12 2018-05-30 Graybug Vision Inc Aggregating microparticles for therapy
US10501517B2 (en) 2016-05-16 2019-12-10 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
MX2019002629A (es) 2016-09-08 2019-10-07 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapéuticos y usos de los mismos.
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
IL267736B2 (en) 2017-01-03 2024-03-01 Intarcia Therapeutics Inc Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
AU2018240462C1 (en) 2017-03-23 2022-12-08 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
MX2019013363A (es) 2017-05-10 2020-01-13 Graybug Vision Inc Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica.
CA3139852A1 (en) * 2019-05-13 2020-11-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Polymer-based implant for retinal therapy and methods of making and using the same
CN112495319B (zh) * 2020-09-29 2023-07-04 海丰生物科技（北京）有限公司 一种环瓜氨酸肽双微球偶联物及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757128A (en) * 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
CH671402A5 (de) * 1985-10-02 1989-08-31 Sandoz Ag
US4789724A (en) * 1986-10-17 1988-12-06 Massachusetts Institute Of Technology Preparation of anhydride copolymers
US5718921A (en) * 1987-03-13 1998-02-17 Massachusetts Institute Of Technology Microspheres comprising polymer and drug dispersed there within
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
JPH09504308A (ja) * 1993-07-23 1997-04-28 マサチューセッツ インスティチュート オブ テクノロジー 非直鎖状の親水性−疎水性マルチブロックコポリマーのナノ粒子およびマイクロ粒子
EP0744940B1 (de) * 1994-02-17 1998-11-11 MODI, Pankaj Arzneimittel, impfstoffe und hormone in polylaktidbeschichteten mikropartikel
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
JP2000143538A (ja) * 1998-11-04 2000-05-23 Teijin Ltd 免疫調節剤を含有する医薬組成物

Also Published As

Publication number Publication date
JP2004538347A (ja) 2004-12-24
WO2003000237A8 (en) 2004-12-23
WO2003000237A3 (en) 2003-03-27
US7163697B2 (en) 2007-01-16
US20030086895A1 (en) 2003-05-08
WO2003000237A2 (en) 2003-01-03
JP4758607B2 (ja) 2011-08-31
AU2002322289A1 (en) 2003-01-08
EP1406593A2 (de) 2004-04-14
EP1406593B1 (de) 2010-08-25
DE60237449D1 (de) 2010-10-07

Similar Documents

Publication Publication Date Title
DE60237449D1 (de) Ammensetzungen und damit in beziehung stehende verwendungen
WO2006063249A3 (en) Functionalized poly (ether-anhydride) block copolymers
DK1553927T3 (da) Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger
BR0112054A (pt) Composição formadora de micelas, e métodos para a administração e a proteção de um agente terapêutico
EP1610751A4 (de) Therapeutisches mittel/ligand-konjugat-zusammensetzungen, ihre syntheseverfahren und ihre anwendung
TNSN06032A1 (en) Pyridazine derivatives and their use as therapeutic agents
DE60230632D1 (de) Pharmazeutische kombinationen von oxycodon und naloxon
TR200102977T2 (tr) Yeni tedavi yöntemi.
DE60023107D1 (de) Zubereitungen mit verbesserter kontrollierter freisetzung
SE9802208D0 (sv) Novel compounds
BRPI0406858A (pt) Liberação controlada de agentes altamente solúveis
NO942396L (no) Preparat med vedvarende frigiving av anti-endotelin substans
ATE454136T1 (de) Therapeutische zusammensetzungen zur pulmonalen verabreichung
GEP20063869B (en) Novel cyclohexyl sulphones
AR034372A1 (es) Composiciones farmaceuticas
DE69627365D1 (de) Verabreichungssystem mit verzoegerter freisetzung sowie langwirkende narkotische analgetika und antagonisten
DK1227797T3 (da) Farmaceutiske faststofdispersionsformuleringer
SE0001916D0 (sv) Novel formulation
WO2005094265A3 (en) Self assembling activation agents targeted using active drug release
AR032036A1 (es) Tratamiento de tumores inoperables por medio de inyeccion estereotactica de microesferas
BR0010699A (pt) Benzimidazóis substituìdos, sua produção e utilização dos mesmos como agente contra protozoários parasitários
IL179544A0 (en) Compositions comprising flavonoids and tocotrienols and methods thereof
PT1307192E (pt) Candesartan para tratamento da enxaqueca
PT1299114E (pt) Composicao farmaceutica de diclofenac com base em vitamina e, papina e hialuronidase
BR0202759A (pt) Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties